X.T.L. Biopharmaceuticals Advances Sickle Cell Treatment with Hillhurst's Phase 2a Trial of HBI-002

Hillhurst Biopharmaceuticals Advances Treatment for Sickle Cell Disease with Phase 2a Trial

Hillhurst Biopharmaceuticals Inc. has marked a pivotal moment in its research efforts by initiating the dosing of the first subject in its Phase 2a clinical trial for HBI-002, an innovative oral therapy designed to treat sickle cell disease. This trial, which began on July 23, 2025, is an open-label study aimed at assessing the safety and tolerability of HBI-002, a low-dose carbon monoxide (CO) therapeutic. Co-founder and CEO Andrew Gomperts underscores the urgency for effective treatments for the debilitating vaso-occlusive crises that plague sickle cell patients, stating that HBI-002 has the potential to significantly alleviate their suffering.

The Phase 2a trial focuses on gathering critical biomarker and pharmacokinetic data, which will provide preliminary insights into HBI-002's efficacy. The outcomes of this trial will inform the subsequent Phase 2b trial set to commence in 2026, further advancing Hillhurst's mission to enhance the quality of life for those afflicted by this genetic disorder. Sickle cell disease is characterized by severe pain crises and potentially life-threatening complications, leading to a reduced average life expectancy of 45 years for individuals in the U.S. Hillhurst’s flagship product candidate, HBI-002, aims to be a chronic home-use solution that not only addresses sickle cell disease but may also extend its therapeutic reach to other inflammatory disorders, such as Parkinson's disease.

Central to Hillhurst's innovation is its proprietary GLASS™ platform, which facilitates the development of novel oral drug products by overcoming the limitations associated with traditional inhaled therapies. This technological advancement positions Hillhurst Biopharmaceuticals at the forefront of biopharmaceutical innovation, particularly in the treatment of chronic conditions such as sickle cell disease. The ongoing support from the NHLBI, through grant number 2R44HL131065-05, signifies confidence in the potential benefits of HBI-002. The first readout from the trial is expected by the end of 2025, which could be a significant milestone in both Hillhurst's research journey and the future of treatments available for sickle cell patients.

In related developments, Hillhurst Biopharmaceuticals continues to explore the broader applications of its GLASS™ platform, indicating potential future innovations in treating other inflammatory diseases. The commitment to addressing the limitations of current therapies reflects the company's dedication to improving patient care and treatment options in the biopharmaceutical industry. With the advancement of HBI-002, Hillhurst is poised to make a meaningful impact on the lives of those suffering from sickle cell disease and beyond.